Sumanirol

Izvor: Wikipedia
Sumanirol
(IUPAC) ime
(R)-5,6-dihidro-5-(metilamino)-4H-imidazo[4,5,1-ij]hinolin-2(1H)-on
Klinički podaci
Identifikatori
CAS broj 179386-43-7
179386-44-8 (maleat)
ATC kod nije dodeljen
PubChem[1][2] 9818479
ChemSpider[3] 7994229
UNII 3E93IV1U45 YesY
Hemijski podaci
Formula C11H13N3O 
Mol. masa 203,240 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status

Sumanirol (PNU-95,666) je visoko selektivni pun agonist D2 receptora. On je prvi otkriveni agonist iz te grupe.[4][5][6]

Sumanirol je razvijen za lečenje Parkinsonove bolesti i sindroma nemirnih nogu. Mada on nije odobren za kliničku upotrebu,[7][8] on je korisno oruđe za bazna istraživanja neurobioloških mehanizama koji su bazirani na modu dejstva dopaminskog D2 receptora (vs. D1, D3, D4, i D5 receptora).[6]

Reference[uredi - уреди]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. doi:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. doi:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. Romero AG, et al. Synthesis of the selective D2 receptor agonist PNU-95666E from D-phenylalanine using a sequential oxidative cyclization strategy. Journal of Organic Chemistry. 1997; 62(19):6582.
  5. McCall RB, Lookingland KJ, Bédard PJ, Huff RM (September 2005). "Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics 314 (3): 1248–56. doi:10.1124/jpet.105.084202. PMID 15980060. 
  6. 6.0 6.1 Weber M, Chang WL, Breier MR, Yang A, Millan MJ, Swerdlow NR (March 2010). "The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 20 (6): 421–425. doi:10.1016/j.euroneuro.2010.02.011. PMC 2864324. PMID 20346635. 
  7. Barone P, Lamb J, Ellis A, Clarke Z (March 2007). "Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease". Movement Disorders : Official Journal of the Movement Disorder Society 22 (4): 483–9. doi:10.1002/mds.21191. PMID 17115380. 
  8. Garcia-Borreguero D, Winkelman J, Adams A, Ellis A, Morris M, Lamb J, Layton G, Versavel M (March 2007). "Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study". Sleep Medicine 8 (2): 119–27. doi:10.1016/j.sleep.2006.05.018. PMID 17239657. 

Spoljašnje veze[uredi - уреди]